Drawing for BIOVERIS SOFTWARE

USPTO serial 76602575

BIOVERIS SOFTWARE

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
SMITH, BRIDGETT G
Law office
TMO LAW OFFICE 115 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with BIOVERIS SOFTWARE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Monica Riva Talley

MONICA RIVA TALLEY FINNEGAN HENDERSON FARABOW GARRETT ET AL901 NEW YORK AVE NWWASHINGTON, DC 20001-4413UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Reagents and diagnostic preparations for scientific and medical research use; research reagents for industrial use, namely, for food testingACTIVE—
005Diagnostic test kits comprised primarily of biological reagents and instruments for use in the detection of agents causing infectious diseases; diagnostic reagents for clinical or medical laboratory use; pharmaceutical preparations, namely vaccines for the treatment of conditions such as diabetes, infectious diseases, cardiovascular disease, and cancerACTIVE—
042Online information in the field of biological measurements; biological measurement, and servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Nov 9, 2005MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Nov 8, 2005ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Mar 2, 2005CPRAPRIORITY ACTION MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Mar 1, 2005CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Feb 17, 2005DOCKASSIGNED TO EXAMINER—
Jul 27, 2004NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance